Loading
Liver Disease Diagnosis and Treatment / Liver Diseases and Immunity · Journal article
Journal of Personalized Medicine · September 8, 2026
A consensus or society position rather than new primary data.
This is a narrative review summarizing current evidence on pediatric MASLD, emphasizing its emergence as the most common chronic liver disease in childhood, its heterogeneous and potentially progressive nature, and the role of personalized medicine integrating multi-omics data for early identification and individualized management. The review does not report new efficacy data but provides expert synthesis of diagnosis, pathophysiology, and therapeutic approaches, with lifestyle modification remaining the cornerstone of management while pharmacological therapies remain investigational.
Journal article. Children with metabolic dysfunction-associated steatotic liver disease; asymptomatic in majority of cases..
MASLD is now the most common chronic liver disease in childhood, paralleling global increases in pediatric obesity and metabolic dysfunction. Disease progression ranges from simple steatosis to steatohepatitis, fibrosis, and rarely cirrhosis, with potential lifelong hepatic and cardiometabolic consequences. Pathogenesis is multifactorial, involving insulin resistance, adipose tissue dysfunction, chronic low-grade inflammation, genetic and epigenetic susceptibility, environmental factors, and gut microbiome alterations.
Pharmacological treatment recommendations remain investigational; no specific agents, dosing, or efficacy figures provided. Lifestyle modification including dietary optimization, increased physical activity, and gradual weight reduction remains the cornerstone of management; pharmacological therapies are still under investigation in pediatric populations.
Clinicians should recognize pediatric MASLD as a heterogeneous and potentially progressive disease warranting early detection and multidisciplinary care. Personalized approaches integrating genomic, epigenomic, metabolomic, and microbiome data may enable better risk stratification and individualized management, though such precision diagnostics and pharmacological therapies require further investigation.
A narrative review synthesizing current evidence on pediatric MASLD epidemiology, pathophysiology, diagnosis, and management, emphasizing personalized medicine approaches rather than reporting new primary research findings.
Clinicians should recognize pediatric MASLD as a heterogeneous and potentially progressive disease warranting early detection and multidisciplinary care. Personalized approaches integrating genomic, epigenomic, metabolomic, and microbiome data may enable better risk stratification and individualized management, though such precision diagnostics and pharmacological therapies require further investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become the most common chronic liver disease in childhood, paralleling the global increase in pediatric obesity and metabolic dysfunction. Once considered a benign condition, pediatric MASLD is now recognized as a heterogeneous and potentially progressive disease that may advance from simple steatosis to steatohepatitis, fibrosis, and, rarely, cirrhosis, with lifelong hepatic and cardiometabolic consequences. Its pathogenesis is multifactorial, involving insulin resistance, adipose tissue dysfunction, chronic low-grade inflammation, genetic and epigenetic susceptibility, environmental factors, and alterations in the gut microbiome. Most affected children are asymptomatic, and diagnosis is often prompted by elevated liver enzymes or incidental imaging findings. Noninvasive tools, including ultrasonography, elastography, serum biomarkers, and emerging multi-omics approaches, are improving disease detection and risk stratification, although liver biopsy remains the reference standard in selected cases. Lifestyle modification, including dietary optimization, increased physical activity, and gradual weight reduction, remains the cornerstone of management, while pharmacological therapies are still under investigation in pediatric populations. The marked variability in disease susceptibility; progression; and treatment response underscores the need for a personalized medicine approach. Integrating clinical characteristics with genomic, epigenomic, metabolomic, and microbiome data may enable early identification of high-risk children, more accurate prognostic assessment, and individualized preventive and therapeutic strategies. Early detection and multidisciplinary care involving pediatricians, hepatologists, endocrinologists, dietitians, and families may help reduce disease progression and the risk of long-term hepatic and cardiometabolic complications. This review summarizes current evidence on the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of pediatric MASLD, with a particular emphasis on precision diagnostics, biomarker discovery, and personalized therapeutic approaches. It also discusses current challenges and future directions for implementing personalized medicine to improve outcomes and reduce the lifelong burden of pediatric MASLD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.